BCDA
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 1.12 · operating margin 0.0%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 131 900 titres (~124 066,00 $ US)
- Insiders
- Altman PeterSTERTZER SIMON H
- Total bought
-
$124,066
Avg buy (VWAP, 90d window) $0.91 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-07-29
- Last synced
-
2026-08-03 21:36:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-23 | Altman Peter | Buy | 1,900 | $1.05 | $1,995 | Form 4 |
| 2026-09-03 | Altman Peter | Buy | 800 | $1.09 | $872 | Form 4 |
| 2026-08-17 | Altman Peter | Buy | 5,400 | $0.93 | $5,022 | Form 4 |
| 2026-08-13 | Altman Peter | Buy | 1,900 | $0.92 | $1,748 | Form 4 |
| 2026-07-29 | Altman Peter | Buy | 5,000 | $0.78 | $3,900 | Form 4 |
| 2026-07-17 | Altman Peter | Buy | 500 | $0.83 | $415 | Form 4 |
| 2026-07-15 | Altman Peter | Buy | 1,500 | $0.86 | $1,290 | Form 4 |
| 2026-07-14 | Altman Peter | Buy | 2,800 | $0.88 | $2,464 | Form 4 |
| 2026-07-10 | Altman Peter | Buy | 1,000 | $0.94 | $940 | Form 4 |
| 2026-07-09 | Altman Peter | Buy | 1,000 | $0.90 | $900 | Form 4 |
| 2026-07-08 | Altman Peter | Buy | 5,400 | $0.96 | $5,208 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-08-03
BCDA presents a critically fragile financial profile — zero revenue, persistent operating losses, and negative cash flows — that overwhelmingly undermines the moderate insider cluster buy signal (131,900 shares, ~$124K).
The first sentence of the analysis written for BCDA on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | -7463.8% | -1519.7% | -553.4% | 36.9% | |
| Ebit Margin | 0.0% | -13700.0% | -2425.8% | -880.3% | -1244.3% | |
| Ebitda Margin | 0.0% | -13584.5% | -2408.2% | -874.2% | -1238.4% | |
| Operating Profit Margin | 0.0% | -13794.8% | -2441.1% | -880.3% | -1244.3% | |
| Pretax Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.6% | |
| Continuous Operations Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.6% | |
| Net Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.4% | |
| Bottom Line Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.6% | |
| Current Ratio | 1.123 | 1.130 | 0.405 | 2.194 | 3.632 | |
| Quick Ratio | 1.123 | 1.130 | 0.405 | 2.194 | 3.632 | |
| Solvency Ratio | -3.067 | -2.729 | -2.503 | -2.413 | -2.351 | |
| Cash Ratio | 1.026 | 1.022 | 0.306 | 2.054 | 3.468 | |
| Price To Earnings Ratio | -1.016 | -0.752 | -1.216 | -9.358 | -7.802 | |
| Price To Earnings Growth Ratio | 0.018 | 0.012 | 0.066 | 0.919 | 0.157 | |
| Forward Price To Earnings Growth Ratio | 0.018 | 0.012 | 0.066 | 0.919 | 0.157 | |
| Price To Earnings Diluted Ratio | -1.016 | -0.752 | -1.216 | -9.358 | -7.802 | |
| Price To Earnings Diluted Growth Ratio | 0.018 | 0.012 | 0.066 | 0.919 | 0.157 | |
| Price To Book Ratio | 9.311 | 7.147 | -8.773 | 22.705 | 9.492 | |
| Price To Sales Ratio | 0.000 | 103.137 | 29.483 | 82.155 | 97.019 | |
| Price To Free Cash Flow Ratio | -1.120 | -0.745 | -1.408 | -10.448 | -9.395 | |
| Price To Operating Cash Flow Ratio | -1.121 | -0.745 | -1.410 | -10.517 | -9.500 | |
| Debt To Assets Ratio | 0.155 | 0.255 | 0.440 | 0.167 | 0.119 | |
| Debt To Equity Ratio | 0.590 | 1.136 | -0.820 | 0.333 | 0.180 | |
| Debt To Capital Ratio | 0.371 | 0.532 | -4.566 | 0.250 | 0.153 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.813 | 4.449 | -1.863 | 2.002 | 1.515 | |
| Working Capital Turnover Ratio | 0.000 | -0.063 | 0.447 | 0.192 | 0.072 | |
| Operating Cash Flow Ratio | -3.058 | -3.458 | -2.764 | -2.946 | -2.793 | |
| Operating Cash Flow Sales Ratio | 0.000 | -138.379 | -20.910 | -7.811 | -10.213 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 1.001 | 1.007 | 1.011 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -1,969.833 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -1,983.500 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -14.083 | -8.440 | -7.585 | -6.475 | -5.549 | |
| Capital Expenditure Coverage Ratio | -1,062.286 | -1,337.667 | -831.167 | -150.871 | -89.362 | |
| Dividend Paid And Capex Coverage Ratio | -1,062.286 | -1,337.667 | -831.167 | -150.871 | -89.362 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.824 | -0.579 | -1.243 | -8.913 | -6.959 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▲7463.8% | ▲1900.0% |
| Ebit Margin | 0.0% | ▲13700.0% | ▲3650.1% |
| Ebitda Margin | 0.0% | ▲13584.5% | ▲3621.1% |
| Operating Profit Margin | 0.0% | ▲13794.8% | ▲3672.1% |
| Pretax Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Continuous Operations Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Net Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Bottom Line Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Current Ratio | 1.123 | ▼-0.006 | ▼-0.573 |
| Quick Ratio | 1.123 | ▼-0.006 | ▼-0.573 |
| Solvency Ratio | -3.067 | ▼-0.338 | ▼-0.455 |
| Cash Ratio | 1.026 | ▲0.005 | ▼-0.549 |
| Price To Earnings Ratio | -1.016 | ▼-0.265 | ▲3.013 |
| Price To Earnings Growth Ratio | 0.018 | ▲0.006 | ▼-0.216 |
| Forward Price To Earnings Growth Ratio | 0.018 | ▲0.006 | ▼-0.216 |
| Price To Earnings Diluted Ratio | -1.016 | ▼-0.265 | ▲3.013 |
| Price To Earnings Diluted Growth Ratio | 0.018 | ▲0.006 | ▼-0.216 |
| Price To Book Ratio | 9.311 | ▲2.164 | ▲1.335 |
| Price To Sales Ratio | 0.000 | ▼-103.137 | ▼-62.359 |
| Price To Free Cash Flow Ratio | -1.120 | ▼-0.375 | ▲3.503 |
| Price To Operating Cash Flow Ratio | -1.121 | ▼-0.375 | ▲3.538 |
| Debt To Assets Ratio | 0.155 | ▼-0.101 | ▼-0.072 |
| Debt To Equity Ratio | 0.590 | ▼-0.546 | ▲0.306 |
| Debt To Capital Ratio | 0.371 | ▼-0.161 | ▲1.023 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 3.813 | ▼-0.636 | ▲1.830 |
| Working Capital Turnover Ratio | 0.000 | ▲0.063 | ▼-0.130 |
| Operating Cash Flow Ratio | -3.058 | ▲0.400 | ▼-0.054 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲138.379 | ▲35.463 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▲0.000 | ▼-0.003 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲393.967 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲396.700 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -14.083 | ▼-5.644 | ▼-5.657 |
| Capital Expenditure Coverage Ratio | -1062.286 | ▲275.381 | ▼-368.015 |
| Dividend Paid And Capex Coverage Ratio | -1062.286 | ▲275.381 | ▼-368.015 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.824 | ▼-0.245 | ▲2.879 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $8.3M | $6.0M | $14.1M | $111.1M | $98.5M | |
| Enterprise value | $6.4M | $4.6M | $14.3M | $105.3M | $87.5M | |
| EV / Sales | 0.00x | 78.65x | 29.93x | 77.92x | 86.18x | |
| EV / Op. cash flow | -0.86x | -0.57x | -1.43x | -9.97x | -8.44x | |
| EV / Free cash flow | -0.85x | -0.57x | -1.43x | -9.91x | -8.35x | |
| EV / EBITDA | -0.82x | -0.58x | -1.24x | -8.91x | -6.96x | |
| Net debt / EBITDA | 0.26x | 0.18x | -0.02x | 0.48x | 0.88x | |
| Current ratio | 1.12x | 1.13x | 0.41x | 2.19x | 3.63x | |
| Income quality | 0.90x | 1.01x | 0.86x | 0.89x | 0.82x | |
| Graham net-net | -$0 | -$0 | -$2 | $2 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.1% | 99.9% | |
| Working capital | $300K | $301K | -$2.1M | $4.3M | $9.8M | |
| Invested capital | $810K | $1.2M | -$791K | $6.0M | $11.8M | |
| Return on assets | -241.1% | -213.4% | -387.4% | -121.6% | -80.3% | |
| Operating ROA | -232.0% | -238.4% | -182.2% | -93.3% | -64.5% | |
| Return on tangible assets | -241.1% | -213.4% | -387.4% | -121.6% | -80.3% | |
| Return on equity | -919.3% | -949.3% | 721.8% | -243.4% | -121.6% | |
| Return on invested capital | -581.7% | -447.5% | 4057.1% | -182.5% | -103.2% | |
| Return on capital employed | -843.8% | -570.3% | 1875.0% | -191.7% | -105.2% | |
| Earnings yield | -98.7% | -132.8% | -82.3% | -10.7% | -12.8% | |
| Free cash flow yield | -89.3% | -134.3% | -71.0% | -9.6% | -10.6% | |
| Capex / Op. cash flow | -0.1% | -0.1% | -0.1% | -0.7% | -1.1% | |
| Capex / Depreciation | 29.2% | 9.0% | 14.3% | 85.4% | 193.3% | |
| Capex / Sales | 0.0% | 10.3% | 2.5% | 5.2% | 11.4% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 501.2% | |
| R&D / Sales | 0.0% | 7563.8% | 1619.7% | 653.4% | 843.2% | |
| Stock comp / Sales | 0.0% | 1277.6% | 215.9% | 87.5% | 163.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 48d | 54d | 53d | |
| Days payables outstanding | 463d | 32d | 42d | 28d | 289d | |
| Operating cycle | 0d | 0d | 48d | 54d | 53d | |
| Cash conversion cycle | -463d | -32d | 6d | 26d | -236d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+39.3%EV / Sales ▼-100.0%EV / EBITDA ▼-42.4%EV / Op. cash flow ▼-0.288Earnings yield ▲+0.341
Profitability
Return on equity ▲+0.300Return on assets ▼-0.277Return on invested capital ▼-1.342Return on capital employed ▼-2.736Operating ROA ▲+0.065Income quality ▼-0.106Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+431.265Operating cycle n/aCash conversion cycle ▼-431.265Capex / Sales ▼-0.103R&D / Sales ▼-75.638
Balance-sheet strength
Current ratio ▼-0.006Net debt / EBITDA ▲+0.075Working capital ▼-1000.000Invested capital ▼-422000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-91.5%EV / Sales ▼-100.0%EV / EBITDA ▲+88.2%EV / Op. cash flow ▲+7.582Earnings yield ▼-0.859
Profitability
Return on equity ▼-7.977Return on assets ▼-1.608Return on invested capital ▼-4.786Return on capital employed ▼-7.386Operating ROA ▼-1.674Income quality ▲+0.083Tax burden +0.000
Efficiency
Days sales outstanding ▼-52.862Days payables outstanding ▲+174.149Operating cycle ▼-52.862Cash conversion cycle ▼-227.011Capex / Sales ▼-0.114R&D / Sales ▼-8.432
Balance-sheet strength
Current ratio ▼-2.508Net debt / EBITDA ▼-0.621Working capital ▼-9469000.000Invested capital ▼-11024000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-07-28 New Strong Sell Stocks for July 28th LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.
- 2026-07-14 New Strong Sell Stocks for July 14th AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
- 2026-06-18 BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company''s Chief Executive Officer, Peter Altman, issued the following letter to shareholders.
- 2026-06-08 BioCardia Announces $4.4 Million Financing Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.
- 2026-06-05 Why Is BioCardia Stock Gaining Friday? BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward potential market approval for its CardiAMP cell therapy.
- 2026-06-05 FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
- 2026-05-21 BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency – Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris.
- 2026-05-15 BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
- 2026-05-15 BioCardia Reports First Quarter 2026 Business Highlights and Financial Results SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management''s formal remarks, there will be a question-and-answer session.
- 2026-05-11 BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 SUNNYVALE, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT.